Skip to main content
Caplight Logo









NDT Biotech

NDT Biotech

Private
AustraliaHealthcare & Life Scienceshttps://ndtbiotech.com/

Last Round

Debt

Jun 1, 2016

Total Funding Raised

$3.3M

Company Overview

NDT Biotech operates in Healthcare & Life Sciences and is based in Australia. Its latest recorded funding round was a Debt round in June 2016.

NDT Biotech is a biotechnology company focused on developing nanoparticle-based therapies for the treatment of melanoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

NDT Biotech Comparables

Compare NDT Biotech with similar companies based on industry and business-model similarity.

NDT Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vitanova Biomedical
77%
Sona Nanotech
77%
Nanospectra Biosciences
70%
Book a demo to see all comparables

For institutional investors. Book with your work email.

NDT Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJun 1, 2016
Series AJul 29, 2011
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

NDT Biotech Investors

Notable investors and investment history

NDT Biotech investors
InvestorRounds
CincyTechSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2016

    $1M debt round completed.

  • Jul 29, 2011

    $2.3M round led by CincyTech.

Book a demo to see all signals

For institutional investors. Book with your work email.

NDT Biotech Filings

Explore SEC and related filing metadata, where available.

NDT Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about NDT Biotech's valuation, stock price, and market status.

Is NDT Biotech a public or private company?

NDT Biotech is a private company.

What is the current stock price of NDT Biotech?

NDT Biotech is a private company, so its shares have no public market price. Caplight tracks NDT Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is NDT Biotech worth (valuation)?

Valuation information for NDT Biotech is not publicly available.

Can I buy NDT Biotech stock?

NDT Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was NDT Biotech's last funding round?

NDT Biotech's most recent funding round was Debt on June 1, 2016.

Who are the main investors in NDT Biotech?

Key investors in NDT Biotech include CincyTech.

Will NDT Biotech IPO soon?

No public IPO plans have been announced for NDT Biotech.

How can I track NDT Biotech secondary market activity?

Caplight tracks bids, offers, and trades in NDT Biotech's shares on secondary markets.

Firmographic Details

HeadquartersAustralia
Year Founded2025
Last FundingJun 1, 2016

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?